The Cost of Integrated HIV Care and Buprenorphine/Naloxone Treatment: Results of a Cross-Site Evaluation
Schackman BR, Leff JA, Botsko M, Fiellin DA, Altice FL, Korthuis PT, Sohler N, Weiss L, Egan JE, Netherland J, Gass J, Finkelstein R. The Cost of Integrated HIV Care and Buprenorphine/Naloxone Treatment: Results of a Cross-Site Evaluation. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s76-s82. PMID: 21317599, PMCID: PMC3270565, DOI: 10.1097/qai.0b013e31820a9a66.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxone treatmentIntegrated care patientsBuprenorphine/naloxoneNaloxone treatmentCare patientsClinic costsIntegrated careCross-site evaluationHIV clinical sitesIntegrated HIV careUrine toxicology analysisMedian monthly costPotential cost offsetsToxicology analysisHIV careIntegrated HIVSimilar patientsPhysician encountersPatient costsClinic settingMedian numberProvider encountersPatient timePatientsClinical sitesDrug Treatment Outcomes Among HIV-Infected Opioid-Dependent Patients Receiving Buprenorphine/Naloxone
Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL, Bazerman LB, Chaudhry A, Cunningham CO, Gourevitch MN, Lum PJ, Sullivan LE, Schottenfeld RS, O'Connor PG. Drug Treatment Outcomes Among HIV-Infected Opioid-Dependent Patients Receiving Buprenorphine/Naloxone. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s33-s38. PMID: 21317592, PMCID: PMC3863630, DOI: 10.1097/qai.0b013e3182097537.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneBuprenorphine/naloxone treatmentOpioid-dependent patientsDrug useOpioid useNaloxone treatmentHIV treatment settingsIllicit opioid useOngoing drug useDrug treatment outcomesNaloxone dosesIllicit opioidsOpioid dependenceOffice visitsProspective studyHIV treatmentRetained patientsTreatment outcomesTreatment retentionPatientsTreatment settingsAddiction treatment processNaloxoneTreatment populationHIVIntegration of Buprenorphine/Naloxone Treatment into HIV Clinical Care: Lessons From the BHIVES Collaborative
Weiss L, Netherland J, Egan JE, Flanigan TP, Fiellin DA, Finkelstein R, Altice FL. Integration of Buprenorphine/Naloxone Treatment into HIV Clinical Care: Lessons From the BHIVES Collaborative. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s68-s75. PMID: 21317597, DOI: 10.1097/qai.0b013e31820a8226.Peer-Reviewed Original ResearchMeSH KeywordsAmbulatory CareAnti-HIV AgentsBuprenorphineBuprenorphine, Naloxone Drug CombinationDelivery of Health Care, IntegratedHealth ResourcesHealth Services Needs and DemandHIV InfectionsHumansNaloxoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPrimary Health CareSubstance Abuse Treatment CentersUnited StatesConceptsBUP/NXHIV clinical careBup/HIV evaluationClinical careBuprenorphine/naloxone treatmentGeneral internal medicine physiciansHospital-based clinicsInternal medicine physiciansSite principal investigatorsExperiences of physiciansMental health issuesPrincipal investigatorHIV providersMultisubstance useNX treatmentHIV careIntegrated HIVNaloxone treatmentUrine toxicologyMultiple prescribersHIV treatmentMedicine physiciansTreatment servicesProvider experience